나눔터
공지사항
의학정보
복지정책
환우회소식
회비 및 후원금 납부내역
헌팅턴병 메뉴얼
HOME > 나눔터 > 의학정보

작성자
huntington [작성일 : 2015-11-23 11:53:49 ]   
제목 안티센스 올리고핵산(ASO; antisense oligonucleotide) 기술을 근간으로 한 헌팅턴병 치료제를 개발
최근 유전자를 조절하는 CRISPR과 함께 현재 임상진행이 들어간 안티센스 올리고핵산(ASO; antisense oligonucleotide) 기술에 대한 소개를 하고자합니다.

안티센스 올리고핵산 기술 은 병원인인 돌연변이 단백질의 유전자 정보만을 저해할 수 있는 기술로서, 헌팅턴병은 물론 다른 질환등의 병원인이 되는 특정 타깃 유전자를 저해할 수 있는 기술입니다.

2013년에 세계적 기업인 로슈(Roche)사가  안티센스 올리고핵산 기술을 바탕으로 헌팅턴병 치료약 개발에 들어갔으며 최근 임상시험을 적용하고 있습니다. 
얼마전 한국에  안티센스 올리고핵산 기술의 대가인 Dr. Don Cleveland가 방문하여 헌팅턴병에서  안티센스 올리고핵산을 이용한 치료 가능성을 설명했으며, 임상시험 결과가 유효하게 나오고 치료약으로서의 안전성 문제 해결 연구가 지속적으로 진행된다면 머지않아 헌팅턴병을 위한 치료제가 나오지 않을까 생각됩니다.



FRIDAY, JULY 24, 2015

Isis Pharmaceuticals launches historic clinical trial to silence Huntington’s disease gene

Isis Pharmaceuticals, Inc., based in Carlsbad, CA, has launched its long-awaited clinical trial to test a drug designed to attack Huntington’s disease at its genetic roots.

In a July 21 press release, Isis said it had initiated a Phase I human clinical study of ISIS-HTTRx, its compound aimed at diminishing the symptoms of HD. HTTRx signifies a medication for HD. The disease is caused by a defect in both the huntingtin gene and protein, which are symbolized by the letters htt.

“ISIS- HTTRX  is the first therapy to enter clinical development that is designed to directly target the cause of the disease by reducing the production of the protein responsible for HD,” the release stated.

In partnership with Roche, the Switzerland-based pharmaceutical giant sharing costs of the typically expensive clinical trial, Isis thus becomes the first entity to use a gene-silencing technique in the attempt to stop HD.

“Although the toxic protein produced from the huntingtin (HTT) gene in HD patients has been a target of interest for many years, no therapies have advanced to clinical trials to treat the underlying cause of the disease,” Frank Bennett, Ph.D., Isis’s senior vice president of research, stated . “Our antisense technology has enabled us to discover and develop ISIS-HTTRx, the first therapeutic approach designed to treat the genetic cause of HD."


Frank Bennett, Ph.D., of Isis Pharmaceuticals (photo by Dr. Ed Wild)

A ‘significant milestone’

HTT Rx  is an antisense oligonucleotide, an artificial strand of DNA created by Isis to block the action of the RNA molecules that translate the huntingtin genetic code to make the huntingtin protein.

Involving about 36 early-stage HD patients at about six sites in Europe and Canada, the Phase I trial focuses on the safety and tolerability of HTTRx. According to an Isis spokesperson, the sites will start recruiting participants as early as in a few weeks.

Depending on the pace of recruitment, Phase I most likely will end in 2017. If Phase I is successful, a larger Phase II trial to test efficacy likely would take place in 2018. A successful Phase II trial would be followed by a Phase III trial. Together all three phases of a clinical trial program typically take at least five years.

Last August, scientists from Isis and CHDI Foundation, Inc., the nonprofit virtual biotech firm that funded the early stages of the Isis research starting in 2007, provided extensive details about the plans for the trial. (Click here to read more.).

“The initial development of this antisense drug for Huntington’s disease came out of a longstanding productive partnership between Isis and CHDI, and its advancement now to clinical trial is testament to Isis’ perseverance and scientific expertise,” CHDI president Robi Blumenstein stated in the press release. “It’s exciting that therapeutic candidates grounded in the biology of Huntington’s disease are finally making their way to clinical trial.”

“The initiation of the ISIS-HTTRx study is a significant milestone in the history of Huntington's disease research as this marks the first time a drug designed specifically for Huntington's patients has transitioned into the clinic,” George Yohrling, Ph.D., senior director for mission and scientific affairs for the Huntington’s Disease Society of America (HDSA), wrote in an e-mail. “My hope is that this study not only shows that the drug is safe, but serves as an informative beacon for all future huntingtin-lowering trials.”

Martha Nance, M.D., the director of the HDSA Center of Excellence at Hennepin County Medical Center in Minneapolis and a member of the executive committee of the Huntington Study Group, said that “it would be impossible to overstate the importance of this trial.”

“I am old enough to have grown up in the 1960s, swept up as a young child with the excitement of space exploration, and I remember, almost as clearly and importantly as the Apollo 11 mission that actually LANDED on the moon, the Apollo 8 mission over Christmas 1968, during which William Anders took the iconic picture of the earthrise over the moon,” Dr. Nance wrote in an e-mail. “There were several more steps, several more Apollo missions, before Neil Armstrong could jump off the ladder onto the moon. The ISIS study is the HD equivalent of the Apollo 8 mission.”

LaVonne Goodman, M.D., the founder of Huntington's Disease Drug Works, said that there are "high hopes and expectations" about the trial. "We celebrate those individuals with HD, heroes who are selflessly participating in this trial and all others, 'taking one for the team,'" she wrote in an e-mail.

“We’re very enthusiastic about the drug,” Dr. Bennett said in a 2014 interview.

As he put it previously, Isis technology is like a “laser-guided missile” that targets a specific, disease-causing messenger RNA and destroys it or takes it out of the body “so that you don’t produce that messenger RNA.”

The Isis-Roche partnership

According to the press release, with the initiation of the clinical trial, Isis – a small company – earned a $22 million milestone payment from Roche. To date, Isis has earned $52 million in upfront and milestone payments from the partnership. It can earn more as the project progresses, as well as royalties on potential sales.

Roche can exercise the option to license ISIS- HTTRx from Isis through the completion of the Phase 1 trial. If so, Roche will assume responsibility for global development, the acquisition of regulatory approvals, and marketing the drug.

The partnership is critical. Isis cannot alone afford to carry out a clinical trial. Drugs usually cost hundreds of millions of dollars to develop.

According to the press release, Isis’s drug projects include 38 drugs aimed at treating a wide range of diseases, among them cardiovascular disease, metabolic disorders, cancer, and severe and rare diseases, including neurological disorders such as HD.

A huge dose of hope

The announcement of the historic trial’s launch provides a huge dose of hope for the HD community.

Since the discovery of the huntingtin gene in 1993, scientists have published thousands of research papers on HD and identified hundreds of potential “targets” for treatments.

In recent years, scientists and drug companies have initiated an increasing number of clinical trials in the quest for effective treatments. However, to date none has proven successful in halting the disease.

A necessary leap

As seen in animal studies, the infusion of HTTRx into the brain has led to the disappearance of the HD-like symptoms.

Scientists warn that it’s a still a huge leap from animals to humans when it comes to testing drugs. Also, only about one in ten clinical trials results in a drug reaching the market.

Earlier this year prominent HD specialist Bernhard Landwehrmeyer, M.D., Ph.D., cautioned that it could still take decades for the gene-silencing approach to play an effective part in managing the disease.

“We should all be extremely excited and hopeful, but remember that there is a lot of work ahead for researchers, doctors, patients, and families before we will get to our moon, and no guarantee of success,” wrote Dr. Nance.

Nevertheless, the Isis-Roche trial is a major step. At a minimum, it will help answer key questions about the gene-silencing approach.

If it is successful in ameliorating symptoms, it could mean the beginning of the end of Huntington’s disease as a threat to the tens of thousands of families affected worldwide.

[ 새글 | 답글 | 수정 | 삭제 ] [ 목록 ]
[ 총게시물 : 120 | page : 6 ]
[ 정렬조건 : 등록일 | 조회  ]
순번 제목 조회 파일 등록일 작성자
120   유전 질환 재단(HDF) 컨퍼런스 2022 – 1일 차 735 22/08/26 운영자  
119   현재 임상 시험 중인 헌팅틴 저하 약물 AMT-130으로 치료받은 일부 사람... 857 22/08/10 운영자  
118   Novartis의 슬픈 소식: branaplam의 VIBRANT-HD 시험에서 투여 중단 682 22/07/24 운영자  
117   헌팅턴병에 대한 유전자 요법에 대한 uniQure의 업데이트 491 22/07/11 운영자  
116   인공 지능? 영리한 컴퓨터가 헌팅턴병을 이해하는 데 얼마나 도움이 됩 641 22/06/28 운영자  
115   헌팅턴병 진행을 추적하기 위한 새로운 로드맵 612 22/06/20 운영자  
114   HD에 대한 비타민 요법 622 22/06/15 운영자  
113   Huntington Study Group 컨퍼런스 발표내용 613 20/11/02 운영자  
112   HTT-C2 692 22/02/03 운영자  
111   고용량 비타민B 보충제 투약 임상실험 619 22/05/19 운영자  
110   헌팅턴병 치료 컨퍼런스 2022 - Day 3 742 22/06/03 운영자  
109   헌팅턴병 치료제 컨퍼런스 2022 - Day 2 658 22/05/27 운영자  
108   헌팅턴병 치료제 컨퍼런스 2022 - Day 1 656 22/05/15 운영자  
107   branaplam 한 숟가락은 헌팅틴 수치를 낮추는 데 도움이 됩니다. 787 22/03/02 운영자  
106   헌팅턴병에 대한 라퀴니모드의 LEGATO-HD 시험에서 나온 실망스러운 소 597 20/02/17 운영자  
105   로슈, '중추적인' 헌팅틴 저하 연구 세부사항 발표 594 20/03/21 운영자  
104   아이들도 때때로 헌팅턴병에 걸립니다 572 20/04/10 운영자  
103   헌팅턴병을 유발하는 단백질과의 전투에서 많은 전선에서 발전 561 20/05/25 운영자  
102   헌팅턴병을 예방하는 유전적 딸꾹질 621 20/05/06 운영자  
101   Roche의 Huntingtin 저하 시험을 위한 업데이트된 시험 디자인 589 20/06/24 운영자  

1 2 3 4 5 6 [ 새글 | 처음목록 | 목록 ]  
단체명 : 헌팅턴병 환우회   주소 : 서울시 종로구 연건동 서울대학교병원  

Copyrightⓒ by huntington.co.kr All rights reserved.    webmaster  개인정보 취급방침